MODERNA INC

NASDAQ: MRNA (Moderna, Inc.)

最近更新时间: 昨天, 1:24PM

25.98

0.97 (3.88%)

前收盘价格 25.01
收盘价格 25.01
成交量 4,251,765
平均成交量 (3个月) 11,388,157
市值 10,151,259,136
价格/销量 (P/S) 4.36
股市价格/股市净资产 (P/B) 1.04
52周波幅
22.28 (-14%) — 48.92 (88%)
利润日期 6 Nov 2025
营业毛利率 -105.67%
营业利益率 (TTM) -972.22%
稀释每股收益 (EPS TTM) -8.73
季度收入增长率 (YOY) -35.30%
总债务/股东权益 (D/E MRQ) 7.40%
流动比率 (MRQ) 4.22
营业现金流 (OCF TTM) -3.05 B
杠杆自由现金流 (LFCF TTM) -3.20 B
资产报酬率 (ROA TTM) -15.84%
股东权益报酬率 (ROE TTM) -29.34%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Moderna, Inc. 混合的 看跌

AIStockmoo 评分

-1.5
分析师共识 -2.5
内部交易活动 NA
价格波动 -2.0
技术平均移动指标 -1.0
技术振荡指标 -0.5
平均 -1.50

相关股票

股票 市值 DY P/E(TTM) P/B
MRNA 10 B - - 1.04
JAZZ 11 B - - 2.76
HRMY 2 B - 11.13 2.30
QURE 2 B - - 7.53
NKTR 1 B - - 15.70
SANA 1 B - - 4.79

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

部门 Healthcare
行业 Biotechnology
投资方式 Small Value
内部持股比例 7.28%
机构持股比例 73.67%
52周波幅
22.28 (-14%) — 48.92 (88%)
目标价格波幅
18.00 (-30%) — 63.00 (142%)
63.00 (Piper Sandler, 142.49%) 购买
25.00 (-3.77%)
18.00 (Leerink Partners, -30.72%) 卖出
平均值 30.78 (18.48%)
总计 2 购买, 4 保留, 3 卖出
平均价格@调整类型 25.12
公司 日期 目标价格 调整类型 价格@调整类型
Leerink Partners 21 Nov 2025 18.00 (-30.72%) 卖出 23.72
Piper Sandler 21 Nov 2025 63.00 (142.49%) 购买 23.72
RBC Capital 21 Nov 2025 25.00 (-3.77%) 保留 23.72
B of A Securities 10 Nov 2025 21.00 (-19.17%) 卖出 24.76
Barclays 07 Nov 2025 25.00 (-3.77%) 保留 24.54
Citigroup 23 Oct 2025 28.00 (7.78%) 保留 26.25
JP Morgan 23 Oct 2025 25.00 (-3.77%) 卖出 26.25
UBS 23 Oct 2025 40.00 (53.96%) 购买 26.25
Morgan Stanley 10 Oct 2025 32.00 (23.17%) 保留 26.83

该时间范围内无数据。

日期 类型 细节
20 Nov 2025 公告 Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
20 Nov 2025 公告 Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
19 Nov 2025 公告 Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities
18 Nov 2025 公告 Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
06 Nov 2025 公告 Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
03 Nov 2025 公告 Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
23 Oct 2025 公告 Moderna Named a Top Employer by Science for Eleventh Consecutive Year
23 Oct 2025 公告 Moderna to Host Investor Event - Analyst Day
22 Oct 2025 公告 Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
19 Oct 2025 公告 Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
16 Oct 2025 公告 Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
12 Oct 2025 公告 Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress
24 Sep 2025 公告 Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
23 Sep 2025 公告 Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
19 Sep 2025 公告 Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
16 Sep 2025 公告 Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
12 Sep 2025 CNBC Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots
05 Sep 2025 CNBC RFK Jr. casts doubts on vaccines, clashes with Democrats over Covid shot access
02 Sep 2025 公告 Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票